Editorials

Does long term aspirin prevent cancer?

BMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c7326 (Published 22 December 2010) Cite this as: BMJ 2010;341:c7326
  1. Paul Moayyedi, professor of medicine1,
  2. Janusz A Jankowski, James Black fellow2
  1. 11200 Main Street West, Hamilton, ON, Canada
  2. 2Division of Clinical Pharmacology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK
  1. janusz.jankowski@clinpharm.ox.ac.uk

Potentially, but trials specifically designed to answer this question are needed

The cardioprotective effects of aspirin are well established. A meta-analysis of individual subject data from primary prevention randomised controlled trials (RCTs) suggested that aspirin can reduce the relative risk of non-fatal myocardial infarction by about 20%.1 Overall, however, the risks of treatment (severe gastrointestinal and extracranial bleeding) were roughly the same as the benefits, so routine use of aspirin as a primary preventive strategy was not recommended. The meta-analysis did not evaluate any potential reduction of mortality from cancer, as has been suggested by observational data.2 Observational data are difficult to interpret, however, because associations may not be causal and may be the result of confounding or bias.3 Rothwell and colleagues have therefore conducted another meta-analysis of individual subject data from RCTs of aspirin versus no aspirin for prevention of vascular disease, but this time they evaluated mortality from cancer as the main outcome.4 They found a 21% (95% confidence interval 8% to 32%) reduction in the odds of death from cancer in people who took aspirin for almost six years, and the effect was strongest for gastrointestinal cancers. The authors …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe